Navigation Links
Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
Date:4/18/2011

BLUE BELL, Pa., April 18, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. (Euronext Paris: FR0005175080) and ChronTech Pharma AB (CTEC.ST) to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) in a phase I clinical study.

It is common to follow an initial "prime" vaccination with a "boost" of the same vaccine to achieve the required level and durability of immune protection. In this collaboration, the strategy is to use different prime and boost vaccines with the goal of obtaining a clinical effect by inducing different immune responses. A Phase I study, to be started later this year, will use ChronTech's ChronVac-C® plasmid DNA vaccine delivered by in vivo electroporation using Inovio's Medpulser® DDS as the "prime" and Transgene's therapeutic vaccine TG4040, a modified vaccinia Ankara (MVA), as the "boost".

DNA based vaccines delivered using electroporation and MVA based vaccines have been separately shown to be safe and immunogenic in clinical studies. The ChronVac-C DNA vaccine delivered by in vivo electroporation using the Medpulser was recently reported to be safe and generate antigen specific immune responses and antiviral effects in a phase I/IIa clinical trial. Rapid virologic responses were seen in 5 out of 7 of the patients receiving a post-vaccination standard of care interferon-ribavirin therapy. TG4040 was itself shown to be safe and immunogenic in a phase I program. Phase II studies in combination with the standard of care are ongoing for both products. In preclinical studies, the novel combination of these DNA and MVA vaccine approaches demonstrated greater immune responses than those obs
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  BioElectronics Corporation (OTC Pink: BIEL), maker ... that Andrew J. Whelan , President will be ... "On Business" at 9am EDT on Wednesday, August 5 ... to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... acceptance the company,s flagship product, ActiPatch Therapy, is achieving ...
(Date:8/3/2015)... Mass. , Aug. 3, 2015 Merrimack ... company will host its Second Quarter 2015 Investor Conference ... 10.    The call will cover an ... of second quarter 2015 financials. A press release detailing ... be issued the afternoon of Monday, August 10. Investors ...
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3
... , , , , , , , ... (Nasdaq and MTA: CTIC) announced today that the European Medicines Agency ... DLBCL which accounts for about 80% of aggressive non-Hodgkin,s lymphoma. ... for approval of pixantrone in mid-2010 and would be granted 10 ...
... DIEGO, Dec. 18 LifeVantage Corporation (OTC Bulletin ... science-based solutions to oxidative stress, announced today that the Company ... Zrii, LLC. Under the terms of this agreement, LifeVantage paid ... on the one hand, and the Company and many individuals ...
Cached Medicine Technology:European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL) 2European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL) 3LifeVantage Announces Settlement of Zrii Litigation 2LifeVantage Announces Settlement of Zrii Litigation 3
(Date:8/3/2015)... ... 03, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today welcomed the announcement by OPKO Health that the US Food ... new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... emergency dental services to help patients in need. Most people know that general health ... hospital emergency. Unfortunately, a fewer amount of people know where to turn to during ...
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... NJ (PRWEB) , ... August 03, 2015 , ... ... to announce the development of it’s new program “Designing Secure Healthcare Systems” ... architects, engineers and technology leaders from healthcare organizations with access to the tactics, ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... genetic risk factor that increases the likelihood that youth will ... of involved and supportive parenting, according to a new University ... issue of the Journal of Consulting and Clinical Psychology ... over time to see how a genetic risk factor interacts ...
... 10 Primary Wave Media, one of the ... announced the creation of its new 1-800-HOSPICE marketing ... care market has become very competitive and these ... Wave,s 1-800-HOSPICE marketing package provides individual hospices with ...
... ZweigWhite,s just-released 2009 AEC Industry Outlook: Strategy and ... shake-up in the markets that firm leaders in the ... most promising. While health care still holds the top ... on project funding, three of last year,s top five ...
... nation, , , TUESDAY, Feb. 10 (HealthDay News) -- A North Carolina ... more than doubled in that state since the early 1990s -- ... country as a whole. , "We were actually surprised by ... medicine at the University of North Carolina and the study,s lead ...
... Sport Science and Management degree programme. The first of its ... produce professionals with relevant knowledge and pertinent skills for engagement ... at facilitating the growth of the sports and leisure industry ... Asia Pacific sports market are evident. According to a global ...
... Alice Jacobs, MD, FACC, FAHA, director of the Cardiac ... is the recipient of the Drake Award. The award ... annual conference in Bethel, Maine. , The Drake ... Eugene Drake, considered to be the first physician in ...
Cached Medicine News:Health News:Study: Genetic risk for substance use can be neutralized by good parenting 2Health News:Primary Wave Media Launches 1-800-HOSPICE 2Health News:New Study Reveals Shake-Up in the Most Promising AEC Markets for 2009 2Health News:Chronic Low Back Pain Is on the Rise 2Health News:Chronic Low Back Pain Is on the Rise 3Health News:Nanyang Technological University launches first-ever sports degree in Singapore 2Health News:Nanyang Technological University launches first-ever sports degree in Singapore 3Health News:Boston Medical Center cardiologist receives Drake Award 2
... Pulse Oximeter and Sensor in one unit providing ... pulse strength measurements on patients from pediatric to ... display, one button keypad and auto power shutdown ... it ideal for emergency, hospital or clinical environments, ...
... The U.S. Food and Drug Administration ... ReSTOR intraocular lens (IOL) for cataract patients ... uses a revolutionary apodized diffractive technology to ... vision (near, intermediate and distance) that greatly ...
... you want: ,Four probe choices, single degree control ... probe in the industry, gives you the power ... to. From full sulcus-to-sulcus measurements to detailed ... the clarity of images and resolution you demand., ...
Engineered for high volume surgical efficiencies, the Bausch & Lomb Hansatome Microkeratome, a corneal resection instrument, features an automated pivoting motion that provides smooth, resistance-fre...
Medicine Products: